1. |
Microdialysis in tissue chemistry monitoring |
|
Inpharma Weekly,
Volume &NA;,
Issue 1329,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
Updated guidelines forHelicobacter pyloriinfection |
|
Inpharma Weekly,
Volume &NA;,
Issue 1329,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1329,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1329,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Tamoxifen plus chemotherapy worth it in early breast cancer? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1329,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Efalizumab: high response rates in plaque psoriasis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1329,
2002,
Page 7-9
Raewyn Poole,
Preview
|
|
摘要:
Efalizumab ['Xanelim'], a humanised anti-CD11a monoclonal antibody that prevents T cell activation, is well tolerated and highly effective in the treatment of moderate-to-severe plaque psoriasis, according to updated results from two pivotal phase III trials presented at the 60th annual meeting of the American Academy of Dermatology (AAD) [New Orleans, US; February 2002]. Combined results from these studies showed that an improvement of ≥ 75% in Psoriasis Area and Severity (PASI) score ('response') was achieved in 27.6-29.2% of efalizumab recipients, compared with 3.4% of patients given placebo. Furthermore, rapid relief from psoriasis symptoms was reported, with improvements noted after administration of the second dose of efalizumab. In extensions of both studies, increased response rates were achieved when the duration of therapy was increased from 12 weeks to 24 weeks. Administration of efalizumab every second week was also shown to be sufficient to maintain responses in patients who had PASI score improvements of ≥ 75% in the initial treatment period.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
Phosphatidylcholine inhibitor G25 shows promising antimalarial activity |
|
Inpharma Weekly,
Volume &NA;,
Issue 1329,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1329,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
Didanosine in paediatric HIV-1 infection |
|
Inpharma Weekly,
Volume &NA;,
Issue 1329,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Psoriasis news from the 60th Annual Meeting of the American Academy of DermatologyNew Orleans, US February 2002 |
|
Inpharma Weekly,
Volume &NA;,
Issue 1329,
2002,
Page 12-13
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|